Nanomosaic Closes A $40.75Mm Over-Subscribed Series A Round
12/06/21, 7:03 AM
Location
bostonMoney raised
$40.8 million
Round Type
series a
NanoMosaic Inc., a Tiger Gene founded company that has established itself as the pioneer and leader in nanoneedle (MosaicNeedleTM) detection for proteomics and multi-omics applications, announced today that it has closed an oversubscribed $40,750,000 Series A round of financing led by RA Capital Management, joined by Insight Partners, Pura Vida Investments, Time BioVentures and Tiger Gene. Aiming to break the bottleneck in protein biomarker interrogation, NanoMosaic has developed a suite of analyte interrogation technologies and has successfully exported its platform to leading hospitals and institutes.
Company Info
Location
boston, massachusetts, united states
Additional Info
NanoMosaic, a Boston-based biotechnology company, is the only commercial entity to leverage the power of nanoneedles, MosaicNeedlesTM, for protein detection and quantification to develop best-in-class assays for biomarker discovery and validation. The NanoMosaic platform, TessieTM, alleviates the bottlenecks in proteomics analysis and provides an end-to-end solution that enables first of its kind protein interrogation and multi-omics analysis within a single chip on one run. The proprietary technology enables rapid, end user customization for assay development for proteomic and/or nucleic acid content. The NanoMosaic platform allows researchers to push the frontiers in biomarker discovery and diagnostics. www.nanomosaicllc.com
CONTACT: Audrey Warner, audrey.warner@tigergenellc.com
SOURCE NanoMosaic